JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, ...
Recent performance snapshot Ligand Pharmaceuticals (LGND) has drawn investor interest after a mixed stretch for the stock, with a 1 day gain of 1.2% contrasting with weaker returns over the past week, ...
Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors ...
LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...
This is my tenth Ligand (LGND) article, following my most recent 06/2025 "Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward". In Powers Forward, I rated Ligand as a "Buy". It has since ...
Learn more about whether Ligand Pharmaceuticals Incorporated or Phibro Animal Health Corporation is a better investment based ...
Ligand Pharmaceuticals was ready to spin off its antibody discovery wing into a new company when special purpose acquisition company Avista Public Acquisition Corp. came knocking. So now, a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results